Showing 3221-3230 of 5646 results for "".
- How Best to Combat Post-Keratoplasty Infections Isn’t Always Clearhttps://modernod.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/Infection is one of the most dreaded complications after ocular surgery. Although it is considered rare, the rate of fungal infections after corneal transplantation is nonetheless increasing in the United States. As detailed in a recent r
- Pfizer Goes Solo on U.S. Shot Distribution, Opting Out of Government Channelshttps://modernod.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/Pfizer had already made it quite clear that it doesn’t need the U.S. government to help distribute its COVID-19 vaccine, should it be authorized by the FDA. Now it’s putting an exclamation point on that declaration, according to a FiercePharma
- Lilly Reaches Deal to Supply US With COVID-19 Antibody Treatment Bamlanivimabhttps://modernod.com/news/lilly-reaches-deal-to-supply-us-with-covid-19-antibody-treatment-bamlanivimab/2478472/Eli Lilly announced that it has signed a $375-million agreement with the US government to supply 300,000 vials of bamlanivimab, an investigational neutralizing antibody treatment for COVID-19. The company recently submitted a request to the FDA seeking emergency-use authorization (EUA) for bamlan
- UK Study Finds Evidence of Waning Antibody Immunity to COVID-19 Over Timehttps://modernod.com/news/uk-study-finds-evidence-of-waning-antibody-immunity-to-covid-19-over-time/2478463/Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found on Tuesday, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community, according to a Reuters
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional
- Bausch Health and BHVI Announce Global Licensing Agreement For Myopia Control Contact Lenshttps://modernod.com/news/bausch-health-and-bhvi-announce-exclusive-global-licensing-agreement-for-myopia-control-contact-lens/2478422/Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI, an Australian not-for-profit organization with an international focus on vision research. Terms of the deal were not disclosed. Bausch + Lomb will pair BHVI’s novel cont
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202